IPO

StickIt Technologies bets on a complex share consolidation and capital raise to survive, but are the terms a red flag for its investors and future?

Following the sale of its legacy business, the newly-rebranded Accendra Health launches on the NYSE with a laser focus on the booming home healthcare market.

Innocan Pharma is set to debut on the NYSE American, aiming to boost its innovative CBD drug delivery platform for non-opioid pain relief. What's next?

From always-on AI in PCs to the core tech in AR glasses, Himax is showcasing the ultralow-power chips that enable the next generation of smart devices.

The crypto payment firm rolled out Ethereum and BNB support, a new Bitcoin explorer, and developer tools in a pivotal year. Is it enough to challenge the giants?

AI drug discovery firm Insilico Medicine soars in its Hong Kong debut, the city's largest biotech IPO of 2025, validating a new tech-driven era for medicine.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

With a 79% drop in net loss and a fourth straight growth quarter, supplement maker Vitality Products Inc. bets on new hires to conquer online and retail.

Starlight U.S. Residential LP finalizes a strategic overhaul and new listing, but a looming loan default on a key property raises critical questions.

All eyes are on Sandisk's Jan 29 report. Can the reborn flash memory leader meet lofty expectations and prove its post-spin-off strategy is a success?

As Wesdome Gold Mines targets mid-tier status, the appointment of financial expert Faheem Tejani signals a strategic move to bolster financial oversight.

A $300,000 financing will fuel Lomiko's push to develop battery-grade graphite in Quebec and explore a strategic antimony-gold prospect in Newfoundland.

MENA's streaming leader Anghami doubles its subscribers after its OSN+ merger, but a $37M loss raises questions about its high-stakes growth strategy.

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

Italian luxury knitwear maker Zanieri completes a reverse merger with Everlert, Inc., gaining a US public listing to fund global expansion and brand growth.

Treace Medical heads to the J.P. Morgan conference to showcase its surgical tech, facing tough questions on growth amid competition and market shifts.

Fitch Ratings awards NETSTREIT a BBB- rating, a milestone affirming its conservative strategy and unlocking new avenues for growth and capital efficiency.

Facing market headwinds, tea supplier Oriental Rise makes a bold move to acquire a major producer, aiming to secure its supply chain and boost quality.

With a new $500 million credit line, Ramaco Resources is doubling down on its unique strategy: growing its coal business while racing to develop a US rare earth mine.

Just months after its IPO, Kandal M Venture is fighting to stay on Nasdaq. We explore the financial woes behind the stock's dramatic fall.